Searching the Main Actors Involved in Human Dementia

About the Research Project
Program
Award Type
Postdoctoral Fellowship
Award Amount
$100,000
Active Dates
July 01, 2013 - June 30, 2015
Grant ID
A2013046F
Mentor(s)
Luciano D'adamio, MD, PhD, Albert Einstein College of Medicine
Goals
Mutations in genes that regulate the processing of the APP protein (the source of Abeta protein) cause early-onset Familial Dementias (FD) in humans. BRI2 is one of these genes. Dr. D’Adamio’s team has generated a mouse model that faithfully represents the human dementias caused by the mutation in BRI2. In this model, APP processing is increased, and leads to memory loss. Given the fact that these mice mirror the genetic defects of patients, they are ideal to dissect the mechanisms that cause dementia in humans. Therefore, this model is suitable for testing therapies for human dementias, including Alzheimer’s disease. In addition, Dr. Del Prete’s studies proposed in this grant application will serve as a preliminary assessment of BRI2-like drugs that could reduce abnormal APP processing without inhibiting the other proteins that mediate the normal processing of APP.
Summary
Alzheimer’s disease (AD) is the most common type of dementia that is clinically characterized as having progressive cognitive deterioration, including loss of memory, reasoning, and language. Mutations in genes that regulate the processing of APP protein cause early-onset Familial Dementias (FD) in humans. All APP disease-causing mutations are located either in the Abeta sequence or near a cleavage site which influences APP processing by different mechanism. Dr. D’Adamio’s team has generated a mouse model that faithfully represents the human dementias caused by the mutation of BRI2 (called FDDKI mice). These mice accurately represent the genetic defects of patients and show an increased APP processing, that leads to memory loss.
The aim of this project is to analyze the domains or fragments of APP involved in the development and progression of disease in FDDKI mice. Dr. Del Prete will study the role of APP processing using genetic and biological approaches. Then, there will be further characterization of the mechanisms by which APP processing and APP-derived metabolites mediate memory deficits in FDDKI mice. The finding that the neurological symptoms of FDDKI mice require the abnormal processing of APP, suggests that this model will help to uncover the disease pathways associated with AD.
The innovation of this research is that the experiments don’t rely on Abeta peptide being the ultimate disease-causing protein; it’s the assessment of all domains or fragments of APP to see if they’re involved in causing disease in FDDKI mice. The ultimate goal is to use the discoveries to develop non-amyloid based targets for therapeutic strategies to produce disease-modifying AD drugs.
Grants
Related Grants
Alzheimer's Disease Research
Tau, Aβ, and Network Degeneration in Alzheimer’s Disease
Active Dates
July 01, 2014 - June 30, 2017
Principal Investigator
Rik Ossenkoppele, PhD
Tau, Aβ, and Network Degeneration in Alzheimer’s Disease
Active Dates
July 01, 2014 - June 30, 2017

Principal Investigator
Rik Ossenkoppele, PhD
Alzheimer's Disease Research
Fingerprinting In Vivo and In Vitro Prion Strains
Active Dates
September 01, 2020 - November 30, 2022
Principal Investigator
Hyunjun Yang, PhD
Fingerprinting In Vivo and In Vitro Prion Strains
Active Dates
September 01, 2020 - November 30, 2022

Principal Investigator
Hyunjun Yang, PhD
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015

Principal Investigator
Guojun Bu, PhD